---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-158454"
form_type: "8-K"
ticker: "CORT"
cik: "0001088856"
company_name: "CORCEPT THERAPEUTICS INC"
filed_at: "2025-07-14T23:59:59+00:00"
generated_at: "2026-05-18T06:36:10.961751+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Corcept submits NDA for relacorilant as treatment for platinum-resistant ovarian cancer

## Summary
- NDA submitted to FDA for relacorilant plus nab-paclitaxel, based on Phase 3 ROSELLA and Phase 2 trials.
- Improved progression-free and overall survival vs nab-paclitaxel monotherapy; no biomarker selection needed.
- Relacorilant well-tolerated; adverse events similar to monotherapy, no increased safety burden.
- CEO notes this is Corcept's second NDA before FDA; relacorilant also under review for hypercortisolism.
- Company preparing launch once approved; oncology and endocrinology units in place.

## SEC filing metadata
- accession: 0001193125-25-158454
- form_type: 8-K
- ticker: CORT
- cik: 0001088856
- company_name: CORCEPT THERAPEUTICS INC
- filed_at: 2025-07-14T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1088856/000119312525158454/0001193125-25-158454-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1088856/000119312525158454/d940113d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-158454
- JSON: https://secwatch.observer/filing/0001193125-25-158454.json
- Plain text: https://secwatch.observer/filing/0001193125-25-158454.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.